Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer

American Journal of Managed Care

Volumn 16, Issue 7, 2010, Pages 515-522

  Obeidat, Nour A ^a   Pradel, Francoise G ^a   Zuckerman, Irene H ^a   Trovato, James A ^a   Palumbo, Francis B ^a   DeLisle, Sylvain ^a,b   Mullins, C Daniel ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE DISPARITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RACISM; RETROSPECTIVE STUDY; ANCESTRY GROUP; COLORECTAL NEOPLASMS; ETHNIC GROUP; ETHNOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 77955484700     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Morris AM, Billingsley KG, Baxter NN, Baldwin LM. Racial disparities in rectal cancer treatment: a population-based analysis. Arch Surg. 2004;139(2):151-156.
2. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-1202.
3. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21(7):1293-1300.
4. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294(21):2703-2711. (Pubitemid 41770099)
5. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20(11):2643-2650. (Pubitemid 34575636)
6. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850-857. (Pubitemid 32590779)
7. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98(9):610-619. (Pubitemid 43904844)
8. Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008;112(4):900-908.
9. Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-Group, Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40(2-3):282-308.
10. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2(6):459-471.
11. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345(8955):939-944.
12. National Comprehensive Cancer Network Web site. NCCN Clinical Practice Guidelines in Oncology: colon cancer. Version 2. 2006. http://www.nccn.org/ professionals/physician-gls/PDF/colon.pdf. Accessed December 24, 2005.
13. Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs. 2007;67(13):1851-1867.
14. Drugs @ FDA: FDA Approved Drug Products Web site. Irinotecan approval history. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist. Accessed December 23, 2005.
15. Saltz LB, Cox JV, Blanke C, et al; Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343(13):905-914.
16. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-1047.
17. Goldberg RM, Sargent DJ, Morton RF. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
18. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
20. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
21. American Cancer Society Web site. Colorectal cancer facts & figures: special edition 2005. http://www.cancer.org/downloads/STT/CAFF2005CR4PWSecured. pdf. Accessed February 27, 2006.
22. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generaliz-ability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
23. Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008;112(4):789-799. (Pubitemid 351240572)
24. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8)(suppl):IV-55-IV-61.
25. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? insight from Surveillance, Epidemiology, and End Results: Medicare. J Clin Oncol. 2001;19(17):3712-3718.
26. Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care. 2000;38(4):411-421.
27. Klabunde CN, Legier JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584-590. (Pubitemid 47096709)
28. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079, 1081-1090.
29. Baldwin LM, Klabunde CN, Green P, Barlow W, Wright G. In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care. 2006;44(8):745-753.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
31. National Cancer Institute Web site. SEER-Medicare: calculation of comorbidity weights. http://healthservices.cancer.gov/seermedicare/program/ comorbidity.html. Accessed March 7, 2008.
32. Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475-3484. (Pubitemid 41103653)
33. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol. 2005;12(8):637-645.
34. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718-726. (Pubitemid 46233233)
35. National Cancer Institute Web site. SEER-Medicare: identification of diagnosis & procedure codes. http://healthservices.cancer.gov/seermedicare/ considerations/identification.html. Accessed July 15, 2007.
36. Cooper GS, Vimig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8)(suppl):IV-43-IV-48.
37. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8)(suppl):IV-19-IV-25.
38. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107(11):2581-2588. (Pubitemid 44845611)
39. Punglia RS, Weeks JC, Neville BA, Earle CC. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information. J Clin Oncol. 2006;24(21):3474-3482.
40. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97(16):1211-1220. (Pubitemid 41258227)
41. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101(10):2308-2318.
42. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemo- therapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24(15):2368-2375.
43. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357. (Pubitemid 34257478)
44. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008;13(8):876-885.
45. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. W Engl J Med. 2004;351(6):575-584.
46. Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD. Residual treatment disparities after oncology referral for rectal cancer. J Natl Cancer Inst. 2008;100(10):738-744.
47. Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology (Williston Park). 2005;19(5):597-602. (Pubitemid 350042590)
48. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008;26(15):2532-2537.
49. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443-1451.
50. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol. 2003;26(1):103-106. (Pubitemid 36205907)
51. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006;24(14):2179-2187.
52. Du XL, Meyer TE, Franzini L. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer. 2007;109(11):2161-2170. (Pubitemid 46801545)
53. Centers for Medicare & Medicaid Services Web site. Medicare Demonstration Projects & Evaluation reports. http://www.cms.hhs.gov/ DemoProjectsEvalRpts/01-0verview.asp#TopOfPage. Accessed December 3, 2009.
54. National Cancer Institute Web site. Cancer Care Outcomes Research & Surveillance Consortium. http://outcomes.cancer.gov/cancors/. Accessed December 3, 2009.